| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| H Y Lane, W H Chan. Clozapine versus risperidone in treatment-refractory schizophrenia: possible impact of dosing strategies. The Journal of clinical psychiatry. vol 60. issue 7. 1999-08-27. PMID:10453806. |
clozapine versus risperidone in treatment-refractory schizophrenia: possible impact of dosing strategies. |
1999-08-27 |
2023-08-12 |
Not clear |
| R de O Oliveira-Souza, R P Marrocos, W M De Figueired. Sustained long-term improvement with clozapine in schizophrenia. Arquivos de neuro-psiquiatria. vol 57. issue 1. 1999-08-26. PMID:10347718. |
sustained long-term improvement with clozapine in schizophrenia. |
1999-08-26 |
2023-08-12 |
human |
| R de O Oliveira-Souza, R P Marrocos, W M De Figueired. Sustained long-term improvement with clozapine in schizophrenia. Arquivos de neuro-psiquiatria. vol 57. issue 1. 1999-08-26. PMID:10347718. |
clozapine should be tried in every patient with schizophrenia in whom positive symptoms, disorganization, or bizarre behavior are a matter of incapacitation despite efforts to keep them under control with other drugs. |
1999-08-26 |
2023-08-12 |
human |
| A Pinto, S La Pia, R Mennella, D Giorgio, L DeSimon. Cognitive-behavioral therapy and clozapine for clients with treatment-refractory schizophrenia. Psychiatric services (Washington, D.C.). vol 50. issue 7. 1999-08-26. PMID:10402608. |
cognitive-behavioral therapy and clozapine for clients with treatment-refractory schizophrenia. |
1999-08-26 |
2023-08-12 |
Not clear |
| C M Kalinya. Schizophrenia treatment: the use of atypical drugs--risperdal, zyperexa, and clozaril. The international journal of psychiatric nursing research. vol 4. issue 2. 1999-08-26. PMID:10451301. |
schizophrenia treatment: the use of atypical drugs--risperdal, zyperexa, and clozaril. |
1999-08-26 |
2023-08-12 |
Not clear |
| C Guitton, J M Kinowski, M Abbar, P Chabrand, F Bressoll. Clozapine and metabolite concentrations during treatment of patients with chronic schizophrenia. Journal of clinical pharmacology. vol 39. issue 7. 1999-08-18. PMID:10392327. |
clozapine and metabolite concentrations during treatment of patients with chronic schizophrenia. |
1999-08-18 |
2023-08-12 |
Not clear |
| H C Kales, J R Dequardo, R Tando. Combined electroconvulsive therapy and clozapine in treatment-resistant schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry. vol 23. issue 3. 1999-08-17. PMID:10378236. |
combined electroconvulsive therapy and clozapine in treatment-resistant schizophrenia. |
1999-08-17 |
2023-08-12 |
Not clear |
| H C Kales, J R Dequardo, R Tando. Combined electroconvulsive therapy and clozapine in treatment-resistant schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry. vol 23. issue 3. 1999-08-17. PMID:10378236. |
to assess the efficacy and safety of combining electroconvulsive therapy (ect) and clozapine in patients with treatment-resistant schizophrenia, the authors reviewed use of this combination in four treatment-resistant schizophrenic inpatients and one inpatient with schizophrenia who was intolerant of clozapine doses needed to control her psychosis. |
1999-08-17 |
2023-08-12 |
Not clear |
| H C Kales, J R Dequardo, R Tando. Combined electroconvulsive therapy and clozapine in treatment-resistant schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry. vol 23. issue 3. 1999-08-17. PMID:10378236. |
the long-term impact of ect on the course of schizophrenia in patients incompletely responsive to clozapine is not fully elucidated. |
1999-08-17 |
2023-08-12 |
Not clear |
| G Facciolà, A Avenoso, M G Scordo, A G Madia, A Ventimiglia, E Perucca, E Spin. Small effects of valproic acid on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenic or affective disorders. Therapeutic drug monitoring. vol 21. issue 3. 1999-08-03. PMID:10365650. |
in a subsequent study, plasma concentrations of clozapine and its metabolites were determined in 6 patients with schizophrenia stabilized on clozapine therapy (200-400 mg/d) before and after treatment with sodium valproate (900-1200 mg/d) for 4 weeks. |
1999-08-03 |
2023-08-12 |
Not clear |
| K Wahlbeck, M Cheine, A Essali, C Adam. Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. The American journal of psychiatry. vol 156. issue 7. 1999-07-30. PMID:10401441. |
evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. |
1999-07-30 |
2023-08-12 |
Not clear |
| K Wahlbeck, M Cheine, A Essali, C Adam. Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. The American journal of psychiatry. vol 156. issue 7. 1999-07-30. PMID:10401441. |
the purpose of this study was to evaluate all available trial-based evidence on the effectiveness of clozapine in schizophrenia as compared with conventional neuroleptics. |
1999-07-30 |
2023-08-12 |
Not clear |
| V Kumari, W Soni, T Sharm. Normalization of information processing deficits in schizophrenia with clozapine. The American journal of psychiatry. vol 156. issue 7. 1999-07-30. PMID:10401450. |
normalization of information processing deficits in schizophrenia with clozapine. |
1999-07-30 |
2023-08-12 |
Not clear |
| V Kumari, W Soni, T Sharm. Normalization of information processing deficits in schizophrenia with clozapine. The American journal of psychiatry. vol 156. issue 7. 1999-07-30. PMID:10401450. |
the authors tested the hypothesis that the use of an atypical drug, clozapine, for patients with schizophrenia is related to less impairment in information processing deficits (assessed by prepulse inhibition of the startle response) than is the use of typical antipsychotics. |
1999-07-30 |
2023-08-12 |
Not clear |
| H Y Meltze. Risperidone and clozapine for treatment-resistant schizophrenia. The American journal of psychiatry. vol 156. issue 7. 1999-07-30. PMID:10401484. |
risperidone and clozapine for treatment-resistant schizophrenia. |
1999-07-30 |
2023-08-12 |
Not clear |
| E Rubi. Risperidone and clozapine for treatment-resistant schizophrenia. The American journal of psychiatry. vol 156. issue 7. 1999-07-30. PMID:10401485. |
risperidone and clozapine for treatment-resistant schizophrenia. |
1999-07-30 |
2023-08-12 |
Not clear |
| E Dunayevich, A Chatterje. Risperidone and clozapine for treatment-resistant schizophrenia. The American journal of psychiatry. vol 156. issue 7. 1999-07-30. PMID:10401486. |
risperidone and clozapine for treatment-resistant schizophrenia. |
1999-07-30 |
2023-08-12 |
Not clear |
| A I Green, S V Zimmet, R D Strous, J J Schildkrau. Clozapine for comorbid substance use disorder and schizophrenia: do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine? Harvard review of psychiatry. vol 6. issue 6. 1999-07-29. PMID:10370435. |
clozapine for comorbid substance use disorder and schizophrenia: do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine? |
1999-07-29 |
2023-08-12 |
Not clear |
| A I Green, S V Zimmet, R D Strous, J J Schildkrau. Clozapine for comorbid substance use disorder and schizophrenia: do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine? Harvard review of psychiatry. vol 6. issue 6. 1999-07-29. PMID:10370435. |
we further suggest that clozapine's beneficial effect in patients with comorbid schizophrenia and substance use disorders may relate to its presumed ability to ameliorate the deficits in both the mesocortical and mesolimbic dopaminergic neuronal projections through its various actions on dopaminergic, serotonergic, and particularly noradrenergic neurons. |
1999-07-29 |
2023-08-12 |
Not clear |
| D A Revick. Pharmacoeconomic studies of atypical antipsychotic drugs for the treatment of schizophrenia. Schizophrenia research. vol 35 Suppl. 1999-07-21. PMID:10190231. |
the current pharmacoeconomic evidence suggests that clozapine is a cost-effective therapy for neuroleptic-refractory schizophrenia and that although olanzapine and risperidone therapy may be cost neutral, they improve outcome in patients treated for schizophrenia. |
1999-07-21 |
2023-08-12 |
Not clear |